DECOY RECEPTORS: Genentech's Avi Ashkenazi suspects that using ligands to bind to decoy receptors present in healthy cells, but not in cancer cells, could trigger apoptosis in tumors.
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?